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Abstract
Background: Painful diabetic neuropathy (PDN), a debilitating and progressive chronic pain condition that
significantly impacts quality of life, is one of the common complications seen with long-standing diabetes mellitus.
Neither pharmacological treatments nor low-frequency spinal cord stimulation (SCS) has provided significant and
long-term pain relief for patients with PDN. This study aims to document the value of 10-kHz SCS in addition to
conventional medical management (CMM) compared with CMM alone in patients with refractory PDN.
Methods: In a prospective, multicenter, randomized controlled trial (SENZA-PDN), 216 subjects with PDN will be
assigned 1:1 to receive 10-kHz SCS combined with CMM or CMM alone after appropriate institutional review board
approvals and followed for 24 months. Key inclusion criteria include (1) symptoms of PDN for at least 12 months, (2)
average pain intensity of at least 5 cm—on a 0- to 10-cm visual analog scale (VAS)—in the lower limbs, and (3) an
appropriate candidate for SCS. Key exclusion criteria include (1) large or gangrenous ulcers or (2) average pain
intensity of at least 3 cm on VAS in the upper limbs or both. Along with pain VAS, neurological assessments, health-
related quality of life, sleep quality, and patient satisfaction will be captured. The primary endpoint comparing
responder rates (≥50% pain relief) and safety rates between the treatment groups will be assessed at 3 months.
Several secondary endpoints will also be reported on.
Discussion: Enrollment commenced in 2017 and was completed in 2019. This study will help to determine
whether 10-kHz SCS improves clinical outcomes and health-related quality of life and is a cost-effective treatment
for PDN that is refractory to CMM.
Trial registration: ClincalTrials.gov identifier: NCT03228420 (registered 24 July 2017).
Background
Globally, 422 million people have diabetes, resulting in USD
$1.7 trillion in direct and indirect costs [1]. According to
data from the Centers for Disease Control and Prevention,
29 million people in the US are currently living with dia-
betes and another 86 million with prediabetes, resulting in
$245 billion in health-care costs and lost productivity [2].
About 20% of patients with diabetes will develop painful dia-
betic neuropathy (PDN) [3], a debilitating and progressive
chronic pain condition that significantly impacts quality of
life.
Peripheral neuropathy from damage to peripheral nerves
may result in pain, numbness, or weakness (or a combin-
ation of these) in the affected limb. Damage may affect
small (myelinated Aδ and unmyelinated C) fibers along
with injury to large myelinated fibers. One of the classifica-
tions for peripheral neuropathy is based on whether the
damage is to a single nerve (mononeuropathy) or multiple
nerves (polyneuropathy). The causes of polyneuropathy
may include metabolic (e.g., chronic renal failure), endo-
crine disorders (e.g., PDN), treatment-induced toxicity (e.g.,
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radiation, chemotherapy, or alcohol-induced neuropathy),
infection (Lyme disease and post-herpetic neuralgia caused
by herpes zoster virus), autoimmune disorders (Guillain–
Barré syndrome and Charcot–Marie–Tooth neuropathy),
compression (carpal tunnel syndrome, tarsal tunnel syn-
drome, ulnar neuropathy, and peroneal neuropathy), and
trauma (trauma-induced neuropathy). Nearly half of cases
of peripheral neuropathy are diagnosed as idiopathic [4].
The American Chronic Pain Association estimates that
more than 15 million people in the US and Europe have
some degree of neuropathic pain. More than 2 in 100 per-
sons are estimated to have peripheral neuropathy; the in-
cidence rises to 8 in 100 for those who are 55 or older [5].
In Europe, the prevalence of PDN ranged from 5.8% to
34.0% [6]. The incidences of PDN were reported to be
0.72 per 1000 persons per year in the Netherlands [7] and
0.64–0.69 per 1000 persons per year in the UK [8]. PDN is
very taxing to the individual patient because of pain, im-
paired quality of life, and increased disability [9, 10] and to
society as a whole because of the significant impact on the
workforce and the increased cost of health care [11, 12]
Anticonvulsant medications, including gabapentin and
pregabalin, are among the most commonly prescribed
medications for neuropathic pain due to PDN [13]. Preg-
abalin, or (S)-3-(aminomethyl)-5-methylhexanoic acid, is
an analog of the inhibitory neurotransmitter gamma-
aminobutyric acid (GABA). It is a compound that acts
on the central nervous system, producing analgesic, anti-
convulsant, and anxiolytic effects. Clinical studies have
demonstrated the effectiveness of this drug in treating
intractable limb pain from PDN resulting from both type
1 and 2 diabetes (Table 1) [14–18, 34]. A review of seven
randomized controlled trials (RCTs) comparing pregaba-
lin with placebo showed marginal benefits over placebo
in decreasing average pain scores: 1.47 cm (placebo),
1.98 cm (150 mg pregabalin), 2.44 cm (300 mg pregaba-
lin), and 2.75 cm (600 mg pregabalin) [35]. The mean
follow-up was 4 to 12 weeks. Responder rates, represent-
ing the percentage of subjects with at least 50% improve-
ment from baseline, varied from 40% to 49%, and placebo
responder rates ranged from 14.5% to 23.0%. Adverse
events (AEs) reported include dizziness, peripheral edema,
somnolence, infection, and weight gain. Approximately
77% of patients prescribed pregabalin for PDN will dis-
continue the treatment within 1 year because of intoler-
able side effects or lack of efficacy [13]. In addition, the
Table 1 Prior randomized controlled trial data for painful diabetic neuropathy
Treatment Number Average baseline pain Average pain post-treatment Responder rate Length of follow-up Reference
Pregabalin 76 6.5 4.0 40% 8 wks [14]
82 6.2 3.6 48% 5 wks [15]
82 6.7 4.3 39% 6 wks [16]
82 6.3 3.5 49% 13 wks [17]
101 6.7 3.7 46% 12 wks [18]
134 6.9 4.3 38% 12 wks [19]
66 6.5 4.8 21% 13 wks [20]
96 NR NR 47% 16 wks [21]
123 7.1 2.0 NR 12 wks [22]
Duloxetine 113 5.9 2.7 52% 12 wks [23]
116 5.5 3.0 50% 12 wks [24]
112 6.2 3.4 53% 12 wks [25]
106 5.5 2.8 57% 12 wks [26]
32 NR NR 59% 8 wks [27]
138 7.1 4.0 42% 12 wks [19]
57 6.6 3.8 NR 8 wks [28]
67 NR NR 28% 16 wks [21]
Tapentadol 199 NR NR 38% 15 wks [29]
12 6.5 3.9 NR 4 wks [30]
168 7.3 4.4 40% 15 wks [31]
Low-frequency SCS 40 7.3 3.1 60% 6 mos [32]
22 7.3 4.0 47% 24 mos [33]
Prior randomized controlled trial data for treatment of painful diabetic neuropathy with reported average pain scores (visual analog scale or numerical rating
scale) and responder rates (reduction in pain of at least 50%). Abbreviations: mos months, NR not reported, SCS spinal cord stimulation, wks weeks
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Neuropathic Pain Special Interest Group (NeuPSIG) of
the International Association for the Study of Pain, which
recently conducted a meta-analysis of 25 RCTs with preg-
abalin treatment of neuropathic pain, calculated that the
number needed to treat (NNT) to achieve 50% pain re-
duction was 7.7 (range of 3.3–45.3); however, the safety
profile for this medication is poor as the number needed
to harm (NNH) is 13.9 [36]. Another commonly used
class of medication for neuropathic pain, including PDN,
consists of the serotonin-noradrenaline reuptake inhibi-
tors (SNRIs). In an analysis of 10 RCTs for SNRIs, includ-
ing seven duloxetine studies, the NeuPSIG reported a
combined NNT of 6.4 (range of 4.2–30.2) and NNH of
11.8.
Low-frequency, paresthesia-based spinal cord stimula-
tion (SCS) has also been shown to be effective in treating
intractable pain associated with many peripheral neuropa-
thies, including RCTs on PDN (Table 1) [32, 33, 37–42].
In a single-center, observational study, Pluijms et al. [39]
reported that the median pain score of subjects treated
with SCS decreased from 6 cm at baseline to 1.8 cm at 3
months on the visual analog scale (VAS) (range of 0–10
cm). However, at 12months, the median pain score in-
creased to 2.9 cm, and slightly over half the subjects (8/15
or 53%) were still responding to the therapy with at least
50% improvement in pain. In another study comparing
SCS with best medical treatment, pain scores measured
with the numerical rating scale (NRS) (range of 0–10) de-
creased from 7.3 and 6.7 (day and night, respectively) at
baseline to 4 and 3.5 at 24months [33]. Responder rates
(subjects with at least 50% pain reduction) ranged from
47% (8/17, day) to 35% (6/17, night). Changes in pain
scores in these studies were deemed to be both clinically
and statistically significant.
Unlike traditional low-frequency, paresthesia-based SCS
that seeks to induce paresthesias in the affected pain distribu-
tion, 10-kHz SCS therapy delivers paresthesia-independent,
high-frequency stimulation by use of a unique waveform and
uniform pulse width [43]. The therapy has demonstrated
safety and superior effectiveness for the treatment of back
and leg pain [44–49] and improved health-related quality of
life [50]; 10-kHz SCS therapy has also been studied for the
treatment of neuropathic limb pain, upper limb and neck
pain, and pelvic pain ([51–54] Burgher A, Kosek P, Surrett S,
Rosen S, Bromberg T, Gulve A, Kansal A, Wu P, McRoberts
WP, Udeshi A, et al, 10 kHz SCS for treatment of chronic
pain of the upper extremities: A post-market observational
study, submitted). In a prospective multicenter study treating
chronic intractable pain of the limbs from peripheral poly-
neuropathy using 10-kHz SCS therapy, subjects reported a
decrease in mean pain score from 7.9 cm (± 0.3 standard
error of the mean [SEM]) at baseline (N= 26) to 2.4 cm (±
0.5 SEM) at 6months post-implant (N= 18), and 78% of
subjects were deemed responders [55].
The current treatments for neuropathic pain second-
ary to PDN are suboptimal and there are substantial
unmet needs [56]. In the proposed study, 10-kHz SCS
therapy plus conventional medical management (CMM)
will be compared with CMM alone for safety, clinical
effectiveness, and cost-effectiveness in treating subjects
diagnosed with chronic, neuropathic limb pain resulting
from diabetic neuropathy. Subjects are allowed to cross to
the alternative treatment arm after 6months if they meet
specific criteria. This protocol represents a pragmatic
study designed to address current evidence gaps and meet
treatment guidelines for the American Diabetes Associ-
ation and the American Academy of Neurology.
Methods/design
This is a multicenter, prospective, randomized controlled
clinical study to document the comparative safety, clinical
effectiveness, and cost-effectiveness of the addition of 10-
kHz SCS therapy to CMM compared with CMM alone in
subjects with chronic, intractable, neuropathic lower limb
pain due to diabetic neuropathy. Enrollment of subjects
will occur at multiple clinical sites only after institutional
review board (IRB) approval and written informed consent
from subjects have been obtained. Central ethical approval
was provided by Western IRB (approval #1176998
received July 20, 2017), and local IRB approvals were
obtained prior to recruiting at the corresponding sites.
Subjects will be selected to participate in the study on the
basis of the protocol’s inclusion (Table 2) and exclusion
(Table 3) criteria. A panel of physician medical monitors
independent of both the study sponsor and clinical inves-
tigator teams will review each consented subject to pro-
vide oversight of appropriate patient selection prior to
randomization. Investigators will conduct the study in
accordance with Good Clinical Practices as outlined in the
US Code of Federal Regulations, the Declaration of
Helsinki (version 2013), and other applicable regula-
tory requirements.
Randomization
Subjects meeting the requirements for inclusion and exclu-
sion criteria will be randomly assigned 1:1 to 10-kHz SCS
therapy delivered by a Senza SCS System (Nevro Corp.,
Redwood City, CA, USA) plus CMM or to CMM alone.
The randomization for each site will be performed by a
block randomization method developed by an independent
statistician. Randomization will be stratified by average
baseline pain VAS score and the baseline hemoglobin A1c
(HbA1c) level. Thus, there will be four strata per site. Con-
cealed allocation will be achieved via computer assignment
of the treatment arm, and investigational site staff and study
sponsor personnel will be unaware of the block size and
randomization list. Owing to the nature of the treatments,
specifically an implanted medical device compared with
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CMM, blinding subjects or investigator teams to the treat-
ment assignment is not feasible. Subjects randomly
assigned to either treatment group will have the potential
to cross over to the alternative treatment arm at the 6-
month visit if they meet all of the following criteria: (1) less
than 50% lower limb pain relief from baseline, (2) docu-
mented subject dissatisfaction with the treatment (“dissatis-
fied” or “very dissatisfied” on subject satisfaction measure),
and (3) investigator agreement with crossover.
Sample size
Up to 432 subjects will be screened at multiple clinical
sites in the US to obtain a total of 216 randomly
assigned subjects, resulting in approximately 108 sub-
jects assigned to each treatment group. Subjects will
continue with their respective treatments through the 3-
month primary endpoint with an expected 10% attrition
rate, resulting in approximately 97 subjects in each
group at the primary endpoint. This is the sample size
required on the basis of the following assumptions: a
60% responder rate for the 10-kHz SCS therapy group
(80% trial success rate and 75% responders at 3 months
among permanent implant subjects), a 36% responder
rate for the CMM-only group, 90% power, and two-
sided type I error of 0.05. Interim analysis will be per-
formed to reassess sample size assumptions when 25%
of the subjects reach the 3-month primary endpoint.
Outcomes assessed
Outcome data will be collected at baseline, trial and im-
plant (10-kHz SCS therapy group), and defined follow-up
intervals (Fig. 1, Table 4). Data collection will include mea-
sures of pain, health-related quality of life, function, subject
satisfaction, health-care utilization, and medication usage,
including treatments for pain relief and diabetic manage-
ment (Table 5). Data will be collected by using electronic
case report forms (eCRFs) via an Electronic Data Capture
(EDC) system (M-Core, Medrio Inc., San Francisco, CA,
USA). Data will be collected by the site research staff and
entered directly into eCRFs in the EDC system at the inves-
tigational sites. The clinical site will record data on out-
come variables as well as AEs should they occur. Subject
confidentiality will be maintained, and each subject will be
identified by his or her subject number.
Statistical analysis
The primary endpoint of this study is a composite of
safety and effectiveness at 3 months, specifically the
percentage of subjects who respond to treatment
without a clinically meaningful neurological deficit
compared with baseline. A responder is defined as a
subject with at least 50% reduction in lower limb pain
from baseline. For each subject and all analyses, the
right and left lower limb VAS scores collected during
a single visit will be averaged together to generate a
lower limb pain score. In addition to the primary
endpoint, several secondary and tertiary endpoints will
be evaluated (Tables 6 and 7).
Descriptive statistics will be used to summarize all
subject baseline and outcome data collected during the
study. Continuous variables will be summarized by using
means, standard deviations, medians, and ranges. Cat-
egorical variables will be summarized in frequency distri-
butions. Statistical tests appropriate to the endpoint
being examined will be used and identified. Parametric
tests (e.g., Student’s t tests) will be used if the distribu-
tional properties of the data are suitable. If parametric
tests are not indicated, the associated non-parametric
tests (e.g., Mann–Whitney tests and Fisher’s exact tests)
Table 2 Inclusion criteria
To participate in the study, subjects must meet all of the following
inclusion criteria:
1. Have been clinically diagnosed with diabetes, in accordance with
the American Diabetes Association guidelines, as well as painful
diabetic neuropathy of the lower limbs, and
a. are symptomatic despite conservative therapy for a minimum of
12 months
b. have tried pregabalin (Lyrica®) OR gabapentin (Neurontin®,
Gralise®, etc.) administered at an adequate dose and for an
appropriate duration in the investigator’s judgement
c. have tried at least one other class of analgesic medication in
addition to pregabalin/gabapentin
d. are on a stable dosage of analgesic medications for at least 30
days
2. Average pain intensity of at least 5 out of 10 cm on the visual
analog scale in the lower extremities at enrollment.
3. Have stable neurological status measured by motor, sensory, and
reflex function as determined by the investigator.
4. Be on a stable analgesic regimen, as determined by the
investigator, for at least 30 days prior to assessing pain intensity as
described in inclusion criterion #2 and be willing to stay on those
medications with no dose adjustments until activation of the
permanently implanted spinal cord stimulation (SCS) device (10-kHz
SCS therapy group) or baseline assessment (conventional medical
management–only group).
5. Be 22 years of age or older at the time of enrollment.
6. Be an appropriate candidate for the surgical procedures required in
this study on the basis of the clinical judgment of the implanting
physician.
7. Be capable of subjective evaluation; able to read and understand
English-written questionnaires; and able to read, understand, and sign
the written informed consent in English.
8. Be willing and able to give informed consent.
9. Be willing and able to comply with study-related requirements, pro-
cedures, and scheduled visits.
10. Have adequate cognitive ability to use a patient programmer and
recharger as determined by the investigator.
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will be used. A two-sided P value of 0.05 or less for the
primary endpoint will be considered evidence of statis-
tical significance. Reported P values for all other tests
will be considered nominal and unadjusted for multiple
testing but without conclusions regarding statistical sig-
nificance levels.
Analysis populations defined for the study include
intention-to-treat (ITT) and per protocol (PP). The ITT
population includes all subjects randomly assigned to
the CMM and CMM plus 10-kHz SCS study groups.
This is considered the safety population for purposes of
reporting on any reported AEs. The PP population
includes all ITT subjects who complete the 3-month pri-
mary assessment. The primary analysis population for
the primary study endpoint is the ITT population. Sec-
ondary analyses will be performed in the PP population.
The responder rates will be compared between groups
with a Fisher’s exact test. Hierarchical testing will be car-
ried out on the secondary endpoints listed in Table 6.
Additional analyses will be performed for subjects who
cross over to 10-kHz SCS treatment by using their data
collected during the initial 6 months of CMM treatment
as a control. Health economic outcomes will be assessed
from health-care utilization, medication, work status,
and health-related quality of life data.
Safety
A clinical events committee (CEC) will be convened to
provide oversight during the study. This expert panel
will serve in an advisory role to review safety data at in-
terim points during the study, including the review of
AEs and adjudication of the relatedness and seriousness
of serious AEs. If needed, the CEC will also review un-
anticipated serious adverse device events on an urgent
basis. The CEC will consist of clinicians with expertise
in pain management, neurology, and endocrinology.
Data review meetings will be held at regular intervals
with the option for an ad hoc meeting at any time if an
Table 3 Exclusion criteria
To participate in the study, subjects must not meet any of the following
exclusion criteria:
1. Have a diagnosis of a lower limb mononeuropathy (e.g., causalgia
and tibial or peroneal neuropathies), have had a lower limb
amputation other than toes because of diabetes, or have large (≥3
cm) or gangrenous ulcers (or both) of the lower limbs.
2. Have an average pain intensity of at least 3 out of 10 cm on the
visual analog scale in the upper extremities because of diabetic
neuropathy at enrollment.
3. Currently have a hemoglobin A1c (HbA1c) of more than 10%.
4. Have a body mass index of more than 45.
5. Currently prescribed a daily opioid dosage of more than 120mg
morphine equivalents.
6. Have a medical condition or pain in other area(s), not intended to
be treated in this study, that could interfere with study procedures,
accurate pain reporting, and/or confound evaluation of study
endpoints, as determined by the investigator (such as primary
headache, fibromyalgia, post-herpetic neuralgia, osteoarthritis,
peripheral vascular disease, or small vessel disease).
7. Have a current diagnosis of a progressive neurological disease such
as multiple sclerosis, chronic inflammatory demyelinating
polyneuropathy, rapidly progressive arachnoiditis, brain or spinal cord
tumor, central deafferentation syndrome, complex regional pain
syndrome, acute herniating disc, severe spinal stenosis, and brachial
plexus injury, as determined by the investigator.
8. Have a current diagnosis or condition such as a coagulation
disorder, bleeding diathesis, platelet dysfunction, low platelet count,
severely diminished functional capacity due to underlying cardiac/
pulmonary disease, symptomatic uncontrolled hypertension,
progressive peripheral vascular disease, or uncontrolled diabetes
mellitus that presents excess risk for performing the procedure, as
determined clinically by the investigator.
9. Have experience with spinal cord stimulation, dorsal root ganglion
stimulation, peripheral nerve field stimulation, or peripheral nerve
stimulation for chronic intractable pain.
10. Have significant spinal stenosis, objective evidence of epidural
scarring and/or any signs or symptoms of myelopathy as determined
by the investigator on the basis of magnetic resonance imaging (MRI)
conducted within the past 12 months.
11. Any history of surgery on the posterior elements (laminectomy,
posterior fusion), resulting in a compromised epidural space, as
determined by the investigator.
12. Be benefitting from an interventional procedure or surgery (or
both) to treat lower limb pain. (Subjects should be enrolled at least
30 days from last benefit.)
13. Have an existing drug pump or another active implantable device
such as a pacemaker or both.
14. Have a condition currently requiring or likely to require the use of
diathermy or MRI that is inconsistent with Senza system guidelines in
the Physician’s Manual.
15. Have either a metastatic malignant neoplasm or untreated local
malignant neoplasm.
16. Have a life expectancy of less than 1 year.
17. Have a local infection at the anticipated surgical entry site or an
active systemic infection.
18. Be pregnant or plan to become pregnant during the study.
Women of childbearing potential who are sexually active must use a
reliable form of birth control, be surgically sterile, or be at least 2 years
post-menopausal.
Table 3 Exclusion criteria (Continued)
19. Have within 6 months of enrollment a significant untreated
addiction to dependency-producing medications, alcohol, or illicit
drugs.
20. Be concomitantly participating in another clinical study.
21. Be involved in an injury claim under current litigation.
22. Be a recipient of temporary Social Security Disability Insurance
benefits because of chronic pain.
23. Have a pending or approved worker’s compensation claim.
24. Have evidence of an active disruptive psychological or psychiatric
disorder or other known condition significant enough to impact
perception of pain, compliance with intervention and/or ability to
evaluate treatment outcome, as determined by a psychologist in the
last 12 months.
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imminent subject safety issue arises. The CEC will have
one physician member representing the study sponsor
and the other physician members will be independent of
the study sponsor and clinical investigators.
Discussion
In the treatment of neuropathic pain secondary to PDN,
10-kHz SCS has the potential to deliver safe and effective
pain relief that is non-pharmacologic and paresthesia-
independent. This would be an important development in
the field because currently available treatment options for
this condition, including pharmacologic agents and con-
ventional SCS, are not adequate for all patients [56].
Pharmacologic options for treating neuropathic pain
include anticonvulsants such as pregabalin, which has
shown clinical efficacy in treating neuropathic pain due
to PDN in high-quality studies [14–18, 34]. These trials
were placebo-controlled and had large sample sizes but
only short-term follow-up (lasting from 4 to 13 weeks).
A study that pooled data from seven pregabalin trials to
improve statistical power found that pain reductions
were modest, the average NRS reduction was 2.75 for
pregabalin (600 mg/day), and a majority of patients
(53%) did not respond to the drug, defined as pain relief
of at least 50% [35]. Duloxetine has also demonstrated
pain relief for PDN in several well-designed RCTs. With
follow-up lasting 8 to 16 weeks, reported responder rates
ranged from 28% to 59% [19, 21, 23–28].
Conventional, low-frequency SCS has also been tested
for treating neuropathic pain in patients with PDN.
Fig. 1 Summary of the sequence of study-related assessments, procedures, and activities
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Table 5 Outcomes
Outcome Variables Reference
Pain
Pain assessment (VAS) 0–10 cm [57]
Responder rates Percentage of subjects with ≥50% pain relief
compared to baseline
NA
Remitter rates Percentage of subjects with ≤3.0 cm pain VAS
for at least 6 months
[58]
Douleur Neuropathique 4 (DN4) 0–10 [59]
Modified Neuropathy Symptom Score (NSS) 0–9 [60]
Brief Pain Inventory for Diabetic Peripheral
Neuropathy (BPI-DPN)
Pain severity: 0–10 [61]
Pain-related interference: 0–10
Short-Form McGill Pain Questionnaire
(SF-MPQ-2)
Continuous pain: 0–10 [62]
Intermittent pain: 0–10
Neuropathic pain: 0–10
Affective descriptors: 0–10
Total: 0–10
Health-related quality of life
Diabetes Quality of Life (DQOL) Impact: 1–5 [63]
Satisfaction: 1–5
Diabetes worry: 1–5
Social worry: 1–5
Total: 1–5
EuroQol Five Dimensions Questionnaire
(EQ-5D-5L)
Index value (US): −0.109-1.0 [64]
Health VAS: 0–100
Global Assessment of Functioning (GAF) 0–100 DSM-IV
Patient Global Impression of Change (PGIC)
and Clinical Global Impression of Change
(CGIC)
No change, almost the same, a little bit better,
somewhat better, moderately better, or a great
deal better
NA
Sleep (PSQ-3) 0–10 cm [65]
Subject satisfaction Very dissatisfied, dissatisfied, not sure, satisfied,
or very satisfied
NA
Medications – Analgesics and Diabetic Control
Medication usage Increased, no change, decreased, eliminated NA
Dosage Average dose over time NA
Function and Health
Six-minute walk test Total meters walked [66]
Shortness of breath: 0–10
Fatigue: 0–10
Body mass index Underweight: <18.5 kg/m2 CDC
Normal: 18.5–24.9 kg/m2
Overweight: 25.0–29.9 kg/m2; obese: >30.0 kg/m2
Hemoglobin A1c (HbA1c) Normal: 4.0%–5.6% ADA
Prediabetes: 5.7%–6.4%
Diabetes: ≥6.5%
Wound healing, including ulcer surveillance Change in greatest diameter over time NA
Health-care utilization Type, reason, and tests/treatments received
during physician, emergency department, and
hospital visits
NA
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Median patient-reported NRS scores were reduced by an
average of 3.1 after 12 months in a small study of 15 pa-
tients [39] and 3.3 after 24 months of stimulation in a
study of 22 patients [33]. Although the long-term dur-
ability of these results is promising, the magnitude of
pain relief was modest, similar to that offered by medica-
tion, and about half of the subjects did not respond to
SCS treatment in each study. These results, combined
with the technical difficulties presented by targeting
paresthesia-dependent stimulation to the feet, support
the development of additional options for treating this
patient population.
The study described here will help determine the effi-
cacy of 10-kHz SCS in patients with neuropathic pain
due to PDN, a currently underserved patient population.
About 100 patients will be randomly assigned to each
treatment arm recruited at multiple sites throughout the
US, which will result in a greater power to detect statis-
tically and clinically meaningful results compared with
prior SCS studies. Follow-up will continue for 24 months
to demonstrate long-term outcomes compared with
prior pharmacological data. Study sites include both
large academic centers and independent pain clinics in
geographically diverse areas that will provide a represen-
tative patient population. A limitation of the study is the
contribution of employees of the sponsor to protocol de-
sign and data analysis as this has the potential to introduce
bias. Multiple measures have been taken to minimize bias:
the participation of outside medical experts in the design
of the study; recruitment of independent physician investi-
gators who are responsible for patient selection, data
collection, and oversight of study conduct at their sites;
concealed allocation of treatment; and the involvement of
the CEC to monitor study safety. The primary endpoint
results will be reported for the ITT population, and sec-
ondary and tertiary outcomes will be reported for the PP
population.
Another potential limitation is the cost of the proposed
treatment in this study versus CMM. SCS is typically an
outpatient procedure during which percutaneous leads
and battery are fully implanted. The device in this study is
rechargeable, and the expected battery life is in excess of
10 years when used at typical therapeutic settings. This
study will collect data on health-care utilization, health-
related quality of life, and medication usage to address
whether the upfront cost for an implanted medical device
can be justified by benefit over the life of the prod-
uct, similar to what has been reported previously for
SCS [67–69] (Additional file 1).
Conclusions
The SENZA-PDN study will be the largest RCT conducted
to date using SCS in subjects with PDN. This prospective
multicenter study will determine whether 10-kHz SCS
improves clinical outcomes and health-related quality of life
and is a cost-effective treatment for PDN. The current
Table 5 Outcomes (Continued)
Outcome Variables Reference
Work status Current employment and reason for not
working, if applicable
NA
Safety
Neurological assessments: lower limb motor
function, L1–S1 sensation to light touch,
pinprick and Semmes–Weinstein 10-g
monofilament sensory testing of the feet,
patellar and Achilles reflexes, Babinski response
Clinically meaningful deficit, no change, or
clinically meaningful improvement in motor,
sensory, and reflexes, compared with baseline
NA
Adverse events Grade I-IV NA
Abbreviations: ADA American Diabetes Association, CDC Centers for Disease Control and Prevention, DSM-IV Diagnostic and Statistical Manual of Mental Disorders -
4th edition, NA not applicable, VAS visual analog scale
Table 6 Secondary study endpoints
1. Difference between the treatment groups in proportion of subjects
with a lower limb pain visual analog scale (VAS) score of not more than
3.0 cm at 3 months.
2. Difference between the treatment groups in crossover rates.
3. Difference between the treatment groups in responder rates at 6
months.
4. Difference between the treatment groups in the proportion of
remitters (remission is defined as having a lower limb pain VAS score of
not more than 3.0 cm for at least 6 months) at 6 months.
5. Difference between the treatment groups in the proportion of
subjects with improvement from baseline in neurological assessment
(motor, sensory, or reflex) at 3 months.
6. Difference between the treatment groups in the proportion of
subjects with overall improvement from baseline in neurological
assessment (motor, sensory, or reflex) at 6 months.
7. Difference between the treatment groups in changes in health-
related quality of life as assessed by the EuroQol Five Dimensions
questionnaire (EQ-5D-5L) at 6 months.
8. Difference between the treatment groups in the average percentage
change from baseline in hemoglobin A1c (HbA1c) levels at 6 months.
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treatments for neuropathic pain secondary to PDN are sub-
optimal and have limited effectiveness and intolerable side
effects. Primary endpoint data are expected in 2020, and
24-month data in 2022.
Trial status
Protocol CA2016–5 US SENZA-PDN-1, revision D (March
19, 2019). The first subject was randomly assigned in
October 2017 and the last in August 2019.
Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.
1186/s13063-019-4007-y.
Additional file 1. SPIRIT (Standard Protocol Items: Recommendations for
Interventional Trials) 2013 Checklist.
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